FDA
-
-
-
-
-
-
-
Advaxis and Ayala Pharmaceuticals Complete Merger
-
-
-
-
-
-
-
Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
-
-
-
-
-
-
-
Advaxis (ADXS) Reports Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial
-
-
-
-
-
-
-
Advaxis to Host Business Update Conference Call on June 11, 2019
-
-
-
-
-
-
-
ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer
-
-
-
-
-
-
-
Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

